Pre-scleroderma: A reversible “phase” in the fibrotic disease

作者: Dhanita Khanna , Arun Shrivastava

DOI: 10.1016/S0973-3698(11)60206-9

关键词:

摘要: 1Consultant Rheumatologist, 2Consultant Immunologist and Sahara Hospital, Lucknow, Uttar Pradesh, India. Correspondence: Dr. Dhanita Khanna, email: dhanitak@yahoo.co.in doi: 10.1016/S0973-3698(11)60206-9 Scleroderma (Scl) is a chronic, idiopathic, fibrosing disorder of connective tissues manifesting characteristically in cutaneous tissues. The “limited” (LSSc) the “diffuse” (DSSc) variants are classified based upon extent skin involvement, although there more reasons to separate two entities immunologically as well predominant sites manifestation internal organs. However, pathogenetically these syndromes appear be related. There rapid progression symptoms diffuse variant within few months years, while limited disease may present only with Raynaud’s phenomenon (RP) for several years before characteristic features becomes apparent. no definite therapy available yet though anti-fibrotic agents, vasodilators, etc. help some extent. Immunosuppression does not have role preventing fibrotic or causing reversal established disease. Therefore, we wonder if reversibility can achieved at early phase process. It prudent differentiate stage this “pre-scleroderma” (pre-Scl) from apparently destined “early” scleroderma. Are diagnose immunologically, pathologically clinically? hypothesised that pre-Scl stage, albeit short, exist DSSc it prolonged LSSc. This most likely manifest onset RP, appearance first non-RP symptom specific Scl “window period” disease; therapeutic intervention here efficacious. would where ischaemic hypoxic changes microcirculation associated tissue beds still devoid chronic reparative processes namely fibrotic/sclerotic changes. Analogous rheumatoid arthritis, also considered early, active which amenable treatment by antiproliferative drugs (ensures vascular potency), antioxidants (prevent re-perfusion injury) possibly immunosuppressive agents (role autoantibodies), could inhibit subsequent target organ damage (fibrosis). Pre-scleroderma approached as: • Diagnostic certainty, Differential mimics, Precipitating events into sclerotic stage.

参考文章(37)
Luggen M, Belhorn L, Fitzgerald O, Spencer-Green G, Evans T, The evolution of Raynaud's phenomenon : a longterm prospective study The Journal of Rheumatology. ,vol. 22, pp. 2226- 2232 ,(1995)
M. Matucci Cerinic, M. Cutolo, Nailfold capillaroscopy and classification criteria for systemic sclerosis. Clinical and Experimental Rheumatology. ,vol. 25, pp. 663- 665 ,(2007)
F.E. Harper, H.R. Maricq, R.E. Turner, R.W. Lidman, E.C. Leroy, A prospective study of raynaud phenomenon and early connective tissue disease: A five-year report The American Journal of Medicine. ,vol. 72, pp. 883- 888 ,(1982) , 10.1016/0002-9343(82)90846-4
Roberto Scarpato, Francesca Cagetti, Gabriella Morozzi, Lucia Migliore, Francesca Bellisai, Giovanni Porciello, Mauro Galeazzi, Roberto Marcolongo, Franca Storino, Clodoveo Ferri, Chromosome aberrations in Raynaud’s phenomenon European Journal of Dermatology. ,vol. 14, pp. 327- 331 ,(2004)
K. Takehara, Y. Soma, Y. Ishibashi, Early detection of scleroderma spectrum disorders in patients with Raynaud's phenomenon Dermatology. ,vol. 183, pp. 164- 168 ,(1991) , 10.1159/000247662
Oliver Schlager, Michael E. Gschwandtner, Karin Herberg, Tanja Frohner, Martin Schillinger, Renate Koppensteiner, Wolfgang Mlekusch, Correlation of infrared thermography and skin perfusion in Raynaud patients and in healthy controls. Microvascular Research. ,vol. 80, pp. 54- 57 ,(2010) , 10.1016/J.MVR.2010.01.010
M Matucci-Cerinic, Y Allanore, L Czirják, A Tyndall, U Müller-Ladner, C Denton, G Valentini, O Distler, K Fligelstone, A Tyrrel-Kennedy, D Farge, O Kowal-Bielecka, F van den Hoogen, M Cutolo, P D Sampaio-Barros, P Nash, K Takehara, D E Furst, The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Annals of the Rheumatic Diseases. ,vol. 68, pp. 1377- 1380 ,(2009) , 10.1136/ARD.2008.106302
Jo N. Fleming, Richard A. Nash, D. O. McLeod, David F. Fiorentino, Howard M. Shulman, M. Kari Connolly, Jerry A. Molitor, Gretchen Henstorf, Robert Lafyatis, David K. Pritchard, Lawrence D. Adams, Daniel E. Furst, Stephen M. Schwartz, Capillary Regeneration in Scleroderma: Stem Cell Therapy Reverses Phenotype? PLOS ONE. ,vol. 3, ,(2008) , 10.1371/JOURNAL.PONE.0001452
Rosalia M. Lomeo, Richard J. Cornella, Stephen I. Schabel, Richard M. Silver, Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis The American Journal of Medicine. ,vol. 87, pp. 525- 527 ,(1989) , 10.1016/S0002-9343(89)80608-4
Jo Nadine Fleming, Richard A. Nash, William M. Mahoney, Stephen Mark Schwartz, Is scleroderma a vasculopathy? Current Rheumatology Reports. ,vol. 11, pp. 103- 110 ,(2009) , 10.1007/S11926-009-0015-3